Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Dutetrabenazine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Teva: Austedo and Austedo XR Data Show Benefits in HD Chorea
    Teva: Austedo and Austedo XR Data Show Benefits in HD Chorea

    05 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/05/3307494/0/en/teva-presents-new-data-on-austedo-deutetrabenazine-tablets-and-austedo-xr-deutetrabenazine-extended-release-tablets-that-show-patient-and-caregiver-reported-improvements-in-hunting.html

    GLOBENEWSWIRE
    05 Jun 2026
    Share Share
    Neurocrine Biosciences Shows INGREZZA Outperforms AUSTEDO XR
    Neurocrine Biosciences Shows INGREZZA Outperforms AUSTEDO XR

    14 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-first-real-world-head-to-head-claims-analysis-demonstrating-greater-treatment-persistence-with-ingrezza-valbenazine-capsules-compared-to-austedo-xr-302741059.html

    PR NEWSWIRE
    14 Apr 2026
    Share Share
    Neurocrine Biosciences Shows INGREZZA Outperforms AUSTEDO XR
    Neurocrine Biosciences Shows INGREZZA Outperforms AUSTEDO XR

    15 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-head-to-head-ingrezza-valbenazine-capsules-data-demonstrating-higher-vmat2-target-occupancy-compared-to-austedo-xr-302661800.html

    PR NEWSWIRE
    15 Jan 2026
    Share Share
    Teva Pharmaceuticals’s Austedo Receives Approval in Europe
    Teva Pharmaceuticals’s Austedo Receives Approval in Europe

    08 Jan 2026

    // EMA

    https://www.ema.europa.eu/en/medicines/human/EPAR/austedo

    EMA
    08 Jan 2026
    Share Share
    Neurocrine's Review Contrasts Tardive Dyskinesia Drugs
    Neurocrine's Review Contrasts Tardive Dyskinesia Drugs

    23 Nov 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/rd/neurocrine-review-highlights-key-differences-between-tardive-dyskinesia-drugs-18317

    INDPHARMAPOST
    23 Nov 2025
    Share Share
    Neurocrine Publishes Review Highlighting Unique INGREZZA Profile
    Neurocrine Publishes Review Highlighting Unique INGREZZA Profile

    20 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-publication-of-landmark-narrative-review-on-fda-approved-vmat2-inhibitors-demonstrating-unique-profile-of-ingrezza-valbenazine-capsules-302620990.html

    PR NEWSWIRE
    20 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.